Santen Corporate (EN)

2019 IR News

RSS

IR News

Santen Announces Topline Result from Phase II Clinical Trial of DE-127 for Patients with Mild and Moderate Myopia
Bayer Yakuhin and Santen Pharmaceutical extend co-promotion agreement for Eylea (aflibercept intravitreal injection) in Japan
Launch of Alesion LX Ophthalmic Solution 0.1% in Japan
Santen Announces Proposed Dividend Change
Santen Reports the 2nd Quarter Fiscal 2019 Consolidated Performance
Santen Donates to the Disaster Caused by Typhoon Hagibis
Receipt of NDA Approval of Alesion LX for anti-allergy in Japan, and Joint Sales Promotion Contract with Mitsubishi Tanabe Pharma
Sponsorship Agreement for IBSA Blind Football Asian Championships 2019 signed between Santen, IBF Foundation, and JBFA
Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients
Santen Reports the 1st Quarter Fiscal 2019 Consolidated Performance
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Corporate Governance Report
Santen Included in All Four ESG Investment Indices Selected by GPIF
R&D collaboration and Option & Licence Agreement with Oxford Biomedica for development of gene therapy vectors for inherited retinal disease
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Santen Chooses SAP S/4HANA Cloud and Other SAP Solutions to Reform Key Operation System and Strengthen Global Management Structure
Notice of Board of Director and Corporate Auditor Nominations
Santen Reports Fiscal 2018 Consolidated Performance
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Santen Announces Launch of LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment in Japan
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Repurchase of Own Shares
Notice of Corporate Officer Appointments
Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
Santen Selected and Launches Gene Therapy Drug Research and Development Project for Inherited Ocular Disease Treatment for CiCLE Program
Santen Selected and Launches Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for CiCLE Program
Santen Announces Status of Repurchase of Own Shares
Santen Announces Repurchase of Own Shares
Santen Reports the 3rd Quarter Fiscal 2018 Consolidated Performance
Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
Santen's Tampere manufacturing facility to be acquired by NextPharma
Santen Updates Pipeline in Corporate Presentation of January 8, 2019